Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,656 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Terminated Phase 3 Interventional

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

NCT00765323
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide Implant, Sandostatin LAR Depot
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Palo Alto, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2013 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

NCT00970502
View directory record Official record
Conditions
Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Neck, Paranasal Sinus Neoplasms, Cancer of the Head
Interventions
erlotinib + celecoxib
Drug
Lead sponsor
Johnny Kao
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 21, 2026, 2:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

NCT03041701
View directory record Official record
Conditions
Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
Interventions
Dasatinib, Ganitumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 21, 2026, 2:04 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Craniofacial Anomalies and Developmental Growth Variants

NCT02639312
View directory record Official record
Conditions
Prognathism, Retrognathism, Dentofacial Deformities
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
2 Years to 100 Years
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2046
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

NCT00694122
View directory record Official record
Conditions
Type 1 Diabetes, Dawn Phenomenon
Interventions
Lantus (glargine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 21, 2026, 2:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 2:04 PM EDT
Recruiting Phase 2 Interventional

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

NCT02491099
View directory record Official record
Conditions
HER2/Neu+ Uterine Serous Carcinoma
Interventions
Afatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
3
States / cities
Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 2:04 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs

NCT01371045
View directory record Official record
Conditions
Acromegaly
Interventions
Oral Glucose Tolerance Test (OGTT)
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

NCT00793975
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMC-1121B, 1121B
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 21, 2026, 2:04 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

ICU Experience in Family Members

NCT02940028
View directory record Official record
Conditions
Post-Traumatic Growth, Psychological
Interventions
Expressive writing, Control writing
Behavioral
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 21, 2026, 2:04 PM EDT
Terminated No phase listed Observational

Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR

NCT00143039
View directory record Official record
Conditions
Hydrops Fetalis, Fetal Growth Retardation
Interventions
Tandem MS test for inborn errors of metabolism
Procedure
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
11
States / cities
Phoenix, Arizona • Laguna Hills, California • Long Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Pamidronate to Treat Osteogenesis Imperfecta in Children

NCT00005901
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Pamidronate (Aredia)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Up to 16 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

Physiologic Growth Hormone Effects in HIV Lipodystrophy

NCT00100698
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
recombinant human growth hormone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Role of Nutrition and Hormones in Boys With Disordered Growth

NCT00102258
View directory record Official record
Conditions
Short Stature, Constitutional Delay of Growth and Development, Dwarfism, Pituitary
Interventions
Growth Hormone Therapy
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 10 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Irvine, California • Los Angeles, California • Newport Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Recombinant Human Platelet-derived Growth Factor in Combination With Collagen Matrix

NCT04462237
View directory record Official record
Conditions
Gingival Recession, Platelet Derived Growth Factor
Interventions
Root coverage procedures
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

NCT02418767
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
MOD-4023, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 21, 2026, 2:04 PM EDT
Withdrawn Not applicable Interventional

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.

NCT00720616
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Norditropin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 21, 2026, 2:04 PM EDT
Completed No phase listed Observational Results available

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

NCT03305016
View directory record Official record
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
6 Months to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23

NCT02020785
View directory record Official record
Conditions
Albuminuria
Interventions
Higher phosphorus period, Lower phosphorus period
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 4 Interventional Results available

Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus

NCT02338609
View directory record Official record
Conditions
Growth and Development
Interventions
Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Saint Paul, Minnesota • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 21, 2026, 2:04 PM EDT
Withdrawn Not applicable Interventional

Extended vs Flexed Elbow Casting

NCT03935516
View directory record Official record
Conditions
Fracture;Elbow
Interventions
Cast
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 21, 2026, 2:04 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer

NCT00193934
View directory record Official record
Conditions
Cancer of the Uterine Cervix
Interventions
Not listed
Lead sponsor
Trans Tasman Radiation Oncology Group
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 21, 2026, 2:04 PM EDT